example, complications of diabetes appear in a substantial fraction of individuals prior to reaching defined diabetes glucose thresholds [5] . Similarly, in osteoporosis, subtle changes in the metabolic balance between bone formation and degradation occur years before bone density measurements are abnormal, or height reductions or fractures are noted at an advanced stage of disease [6] .
Late-stage disease interventions are palliative, often attempting to address multiple acute symptoms that require expensive treatments and resources. An important goal of medical research is to develop tests that can detect the early stages of complex diseases when intervention can prevent or delay disease progression, and irreversible damage can be minimized [3, 7, 8] . In a note about doctors' views on wasting disease Niccolo Machiavelli observed in 1521 that "As the doctors say of a wasting disease, to start with it is easy to cure but difficult to diagnose; after a time, unless it has been diagnosed and treated at the outset, it becomes easy to diagnose but difficult to cure" [9] . It remains true of many other medical conditions in the present time.
Unfortunately, the etiology of complex diseases involves multiple biological pathways, and their early stages are rarely identified well by single biomarkers, regardless of biomarker class. For a complex disease such as Type 2 diabetes, where metabolic, inflammatory and Microfluidic strategies applied to biomarker discovery and validation for multivariate diagnostics Complex diseases are caused by combinatorial genetic, environmental and lifestyle factors. The emergence of multibiomarker tests to define these diseases and to identify the early, presymptomatic stages offers several advantages to the conventional use of single marker tests. The development of multibiomarker protein-based tests remains constrained by technological and operational limitations in assaying hundreds to thousands of proteins in thousands of samples. In order to develop a multibiomarker test that stratifies risk for Type 2 diabetes, we took a candidate-driven immunoassay approach utilizing a microfluidics platform to analyze 89 candidate proteins in thousands of samples, which allowed us to move from discovery to a commercial test in 2 years. Future multibiomarker test development will be enhanced by advancements in the number of proteins that can be analyzed, analytical sensitivity and throughput, and sample volume requirements, all of which depend on the further advancement of microfluidics, detection technologies and affinity-based reagents.
hormonal biological pathways contribute along with environment and lifestyle factors, it is not surprising that using a single biomarker that captures only one facet of disease pathology does not stratify risk well. Although practical and simple to implement (e.g., blood glucose for Type 2 diabetes, prostate-specific antigen for prostate cancer), single biomarker tests often lack the appropriate sensitivity and/or specificity needed for early-stage disease detection. While there will always be some proportion of false-positive and false-negative results for any diagnostic method, multimarker tests have the potential of reducing both the number of high-risk patients left unidentified (false negatives) and the number of patients receiving unnecessary interventions (false positives).
The hypothesis that diagnostics based on a set of biomarkers will have better performance in identifying the early stages of complex diseases [10] has been explored in several disease areas, including cardiovascular disease [11] [12] [13] [14] [15] , Alzheimer's disease [16, 17] , stroke [18] , breast cancer [19] [20] [21] [22] and prostate cancer [23] . With notable exceptions [15, 22, [24] [25] [26] , adoption of multibiomarker tests in routine clinical practice has not yet been achieved.
In order to construct a useful set of 5-10 biomarkers for a desired commercial test, it can be necessary to investigate tens to hundreds of biomarker candidates in clinical sample banks. The challenge is often in the type (e.g., serum, cells and fixed tissue) and amount (e.g., 100 µl, 5 ml and a microtome slice of tissue) of clinical sample that is available or that can be collected. For the work conducted at Tethys to find predictive algorithms for disease occurrence 5 or more years in the future, it was necessary to use serum samples collected many years ago from individuals for whom the long-term outcomes are now known. The alternative, to prospectively collect samples and wait for outcomes, is prohibitively time and cost consuming. These irreplaceable samples were in very limited supply, and often no more than 500 µl was available. For reasons that will be discussed, our desire was to use protein biomarkers. Conventional immunoassays were not capable of reaching either the molecular limits of detection or limits of quantitation necessary to quantify nearly 100 protein candidates within such small sample volumes. That led us to adopt a microfluidics platform, the subject of this article, where assays could be performed with excellent molecular detection and quantitation limits using low sample volumes.
Our research group explored the available strategies for identifying a set of biomarkers that could identify individuals at high risk for developing Type 2 diabetes at a stage where interventions could potentially delay or prevent the onset of overt disease. This article presents our experiences in this biomarker development program in order to highlight some of the challenges of discovering and validating biomarker sets and associated algorithms. We also describe how parallel processing coupled with advances in microf luidics enabled a successful program, and how future advances in microfluidics, detection technologies and affinity reagents will continue to expand the experimental strategies for developing protein biomarker panels. We believe the approaches described here are broadly applicable to the development of multibiomarker panels.
Biomarker classes
The term biomarker is applied loosely to anthropometrics, physiological measurements, physical conditions (e.g., age or disease), imagebased measurements and measurements of molecules. To be of value, a molecular biomarker should be relatively easy to measure within readily available biological sample types and associated with disease risk, status, intervention guidance or response. Many molecular forms of biomarkers were considered in planning our molecular biomarker discovery program for risk of Type 2 diabetes, including DNA, RNA, metabolites and proteins. In determining which species of biomarker to pursue, we took into consideration the relevance and clinical utility of different biomarker classes to the disease state, as well as the technical and practical considerations of measuring them within specific biological sample types. We also sought dynamic biomarkers that might change with an actual change in risk due to successful intervention.
It seemed questionable that genetic biomarkers would have sufficient predictive power for a disease with such a strong environmental and lifestyle component [27] . The extensive work in genome-wide genetic analyses has demonstrated how difficult it is to create multivariate genetic tests that are sufficiently predictive of Type 2 diabetes [28] [29] [30] . Changes in lifestyle have a dramatic effect on risk for diabetes, but this is not reflected in genetic biomarkers, or in classic risk factors such as gender and age.
RNA biomarkers also have several drawbacks. From a practical perspective, RNA testing is
Key Terms

Intervention guidance:
Selection of the most appropriate intervention, such as the best therapeutic, medical procedure, or lifestyle change.
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The fraction of a set (e.g., a proteome) that is addressed or analyzed in any one experimental approach.
Hypothesis-driven and hypothesis-free:
Hypothesis-free approaches use unbiased methods that do not require prior knowledge of a biomarker's (e.g., a protein) role in the disease or biological process of interest to filter what biomarkers be able to detect or measure its level (e.g., MS). Hypothesis-driven approaches use biased methods which require knowledge of the biomarker to be able to detect or measure it (e.g., immunoassays require specific antibodies to detect particular proteins). dependent on preserving RNA from tissue or blood samples and none of the completed longterm Type 2 diabetes outcome studies that we located had banked cells or RNA. Future studies of potential RNA markers using prospective studies will have to wait for several years until there are a sufficient number of diabetes outcomes available. We, therefore, planned to focus on proteins and metabolites with the anticipation that levels of these biomarker classes represent the cumulative product of genetic, environmental and behavioral inf luences, and would be an accurate representation of a physiological snapshot of an individual. Furthermore, since these biomarker species can be altered directly by lifestyle and therapeutic interventions, they have the potential to not only define prognostic status but also the molecular signature of response to interventions. On a more practical note, the detection of proteins, metabolites and other small molecules is a mainstay of current clinical diagnostics. In addition these biomarker species are present within serum or plasma, both practical and commonly employed clinical specimens available from retrospective clinical study sample banks as well as from routine clinical practice. Availability of appropriate sample banks for biomarker discovery and validation was a prerequisite for developing a robust test. Familiarity with these biomarker types within the medical community and the wide availability of instrumentation to measure such molecular biomarkers should facilitate their adoption into routine laboratory and clinical practice.
While both the metabolome and proteome offer large numbers of potential biomarkers and are equally important to evaluating disease, for the purposes of this article we will focus on efforts to discover and validate novel protein biomarkers in combination with commonly measured metabolite biomarkers for use in multivariate diagnostic tests. See [31, 32] for review of metabolomic approaches to biomarker discovery. Figure 1 illustrates the four main stages in the research and development of multibiomarker tests, which include discovery, research validation, clinical validation and commercialization. We have found these stage definitions to be useful in our R&D programs to clarify objectives and technical requirements. Each stage is dependent on the constraints of current technologies and/or the availability of samples. In the first two research phases, the goal is to identify a set of biomarkers that can be combined for the intended use and to prove that they work in a population sufficiently representative of the target population such that the costs and risks of development are mitigated. In the development phases, the focus is the transfer of assays to commercial platforms, calibration of a multivariate algorithm and validation of the performance of the biomarker panel in additional populations, such that clinical utility is well supported.
Development of multibiomarker tests for chronic diseases
Research
Our goal in the research phases was to examine as many candidate protein biomarkers in blood as was practical, and to understand which set of biomarkers best stratified individual risk for developing Type 2 diabetes. A critical and challenging issue in developing complex chronic disease diagnostics, is the availability of appropriate sample banks that have been well documented, well handled, have associated chronic disease outcomes and have available sample types. While a number of easy-toobtain sample types, such as urine or saliva, were theoretically possible to use as a clinical sample type, blood was ultimately chosen. Blood transports a huge variety of substances from and toward all tissues and harbors a massive amount of information about the status of health [33] . In addition, blood is the most commonly stored sample type in the existing sample collections that would be used in discovery and validation studies.
A discovery phase that incorporates an unbiased proteomic strategy is arguably the best approach, assuming it has sufficient proteome coverage, sensitivity, throughput and reproducibility. Unfortunately there are no platforms available that enable truly hypothesisfree proteomics discovery in complex samples that meet these performance requirements. While MS is generally considered a reliable technology for qualitative proteomics, it still suffers from challenges related in the reproducible quantification of proteins in complex samples, particularly when trying to resolve protein concentrations that span several orders of magnitude. While multiple reaction monitoring and other techniques can be used to increase the performance of quantitative MS [34] , the sample volume requirements (e.g., 10 ml) for quantitative The primary goal would be to understand which molecules statistically performed best both alone (univariate) and in combination (multivariate), relative to clinical benchmarks. Our preferred approach is to conduct a broad Discovery process on a subset of samples noting candidate biomarkers that show the greatest performance. We then combine those candidates in a larger research validation experiment with many times more samples in order to develop multivariate models. This is far less expensive and sample volume intensive than a very broad study with all candidate markers and the full clinical sample set. Perhaps the later approach will be practical one day with new technical approaches (see later). Multiple cohorts of samples with outcomes are highly desirable for separate training and validation of algorithms.
Our technical challenge was to conduct quantitative immunoassays on 50 -200 proteins over a dynamic range of nearly ten orders of magnitude with only small volumes of blood samples.
Development considerations
The aims of the research phases and, therefore, the number of candidates and number of samples to analyze are quite different from the development phases (Figure 1 ). These differences create different performance requirements for the technology platforms that can be used. The changes in the resources and skill sets required when moving from research to a commercial diagnostic product are important to recognize [10] . While devising the research and development plan, we paid careful attention to how the clinical validation phase could be conducted. Clinical validation is very different from research validation, in that research validation typically takes place on a research analytical platform, and clinical validation takes place on the platform that the commercial test will be run on. During research, low volumes of sample are a typical constraint and the number of samples to be run are modest compared with the commercial product (Figure 1 ). The commercial platform must be far more robust and cost effective (e.g., cost per assay) than a research platform. In addition, the clinical validation must incorporate a commercial tests target population and intended use. Typically different systems are required for research versus commercialization. In our experience, attempts to use one system for both typically compromise one or the other phase.
Development has been particularly challenging for the medical community to overcome, as academic institutions (where mostly discovery efforts tend to occur) do not generally have the resources to perform research validation studies, let alone the development phases of clinical validation and commercialization. Diagnostics companies (where most clinical validation and commercialization efforts occur) are often reluctant to take on a significant risk to invest resources in discovering or validating biomarkers that might never turn into diagnostic products [35] . These gaps in resources, skill sets, and motivations are thought to account for the fact that the number of diagnostics to measure newly-identified protein biomarkers has trailed off in recent years, and is not at all what might have been expected given the resources and efforts that had gone into protein biomarker discovery efforts in the last 10 years. Both Herr [36] and Zolg [37] argue that the process of thorough ana lysis of biomarker candidates in well-planned studies is a major challenge hampering the progress of converting many biomarker candidates into commercially successful diagnostics.
Selection of the research technology platform
Choice of a commercial platform is beyond the scope of this article, but, as stated, requires rather different criteria. In our own work, we chose existing commercial systems [38] . Based on the experiences outlined above, we have developed a set of criteria to consider when choosing a platform for molecular biomarker discovery and research validation efforts. These include operational issues, such as costs (capital, labor and reagents), instrument robustness, ease of assay development, reproducibility, scalability, ability to automate, sample tracking, data flow and transfer of assays to development, manufacturing and commercial use. Weighting for each of these will be specific to a laboratory or manufacturer given their individual cost structures and capabilities. For the purposes of this article, we focus upon the technical performance characteristics as they relate to large-scale protein biomarker discovery and research validation, where the main technical constraints are the sample volume required, performance and ease of assay development.
Figure 2 is a flow diagram for the overall research process starting from sample acquisition and ending with a panel of biomarker candidates for commercialization. The process takes from 18 to 36 months, with a great deal of the time spent on acquiring samples from an appropriate set of cohorts. The entire selection process is dependent upon the amount and number of clinical samples that can be obtained (even for retrospective samples this is often the rate-limiting step).
For Type 2 diabetes, the incidence in an unselected adult population is 3-5% over 5 years. Therefore, in order to have 200 individuals who develop diabetes (outcomes) within the study cohort, it is necessary to start at baseline with 4000 to 6000 nondiabetic subjects. The opportunity to use samples for which the outcomes have already been collected (i.e., a retrospective study) is a critical factor from a commercial perspective that is generally underappreciated. Initiating a prospective study of 6000 subjects that requires more than five years to collect the outcomes can cost more than US$100 million. Typically studies of this size can only be resourced by large pharmaceutical companies or through government-scale grants. The ability to conduct the discovery process in a meaningful time frame, therefore, depends upon access to samples from these valuable cohorts.
It should be appreciated that the amount of sample available from these outcome studies is Microfluidic strategies for biomarker discovery & validation for multivariate diagnostics | Review www.future-science.com extremely limited. In this context, the speed of the analytical platform is a secondary concern. What matters most is generating data of the highest possible quality (e.g., accuracy and precision) while conserving the precious and irreplaceable samples being used. Traditional ELISA approaches require 10-50 µl per individual protein assay, which would necessitate the use of between 1.5 and 7.5 ml to measure the concentration of 50 proteins in triplicate. This is an unrealistic proposition for the cohort managers who have spent 10 years funding, designing, organizing and carefully banking samples from thousands of subjects across multiple time points. A more realistic request is typically 0.5 ml or less per subject. For these reasons, standard ELISA formats are not practical when the goal is to analyze a large number of candidate biomarkers in small quantities of sample. Analytical performance is a key issue when searching for biomarkers that differentiate disease and nondisease states. Discrimination of a clinical outcome -whether measured using likelihood ratios, odds ratios or sensitivity/ specificity measures -are all dependent on the ability of a technology to accurately and precisely measure the biomarkers of interest. Low-abundant yet potentially informative biomarkers have historically been difficult to assay due to the quantitative limits of discovery technologies. Biomarkers that are present at concentrations below the limits of quantification for a technology either do not generate a disease-related signal or, worse, introduce a random error-based signal that is not related to the underlying biology of the disease state. Both scenarios negatively impact the discovery process -potentially informative biomarkers are lost while uninformative analytes are falsely identified as biomarkers. Even for biomarkers that are within the quantitative limits of the technology, precision often scales with the abundance of the analyte. Low-precision measurements can, in some cases, be worse than no measureable signal at all, as inaccurate estimates can often lead to false positive findings [39] . The effect of measurement errors typically seen in quantitative immunoassay technologies, where the coefficient of variation (CV) is often 10-15%, can be reduced by increasing the number of samples analyzed and/or the number of measurements taken from each sample. However, these strategies are typically not feasible due to constraints in resources. For these reasons, many proteomic discovery technologies use fold-change limits (e.g., >1.5-to 3-fold) on signals they consider to be truly indicative of effect-size. However, the use of fold-change limits largely precludes the discovery of many low-abundant yet potentially informative biomarkers due to the analytical inaccuracies discussed earlier.
Finally, in selecting an analytical platform, the ease of assay development should be taken into account. The development of sandwich immunoassays is a complex and demanding effort and involves the evaluation of antibodies, epitope pairs, buffer conditions and isoforms of the protein. The primary constraints are usually the quality of the capture reagent and the abundance of the protein biomarker. Multiplexing adds to the complexity of assay development since the components of the assay cannot cross-react, must work in the same buffers, blockers and salts, and the analytes should be in the same approximate range of linear assay performance for a given serum concentration. A singleplex assay has three basic components that must work well together, a 5-plex immunoassay has 15 components, and a 10-plex assay has 30 components. In other words, the number of pair-wise interactions to consider goes from three to 105 to 435. This puts constraints on assay performance that inevitably introduces compromises in analyte sensitivity, specificity and precision. In our program, fewer than half the candidate biomarkers that we were interested in measuring were available in any commercial format, and the prospect of developing a large number of high-quality assays in a multiplexed format would have required excessive resources. Therefore, we reasoned that we would obtain better data in a shorter time frame by purchasing existing singleplex assay reagents, and developing new assays in singleplex format, rather than trying to develop and re-develop multiplex assays for every new assay that was introduced.
There are a number of technologies we ruled out since, at that time, they did not meet our performance requirements. These included antibody arrays [40] , proximity ligation assays [41] and antigen-down assays [42] , as well as standard ELISA formats, although all of these technologies are useful for other purposes. Table 1 shows the three technologies we considered to have potential for our work. They are all based on the sandwich ELISA format, but detect the molecules in completely different ways. The 19) electrochemiluminescence approach, which is not a microfluidic method, adsorbs the primary antibody to an electrode and an electrochemical reaction based upon a very stable, substitutioninert rubidium coordination complex that drives luminescent light via a reporter molecule on the secondary antibody. Single molecule counting (SMC; Figure 3) dissociates the sandwich product after extensive washing, and then the fluorescently-labeled secondary antibody is sipped into microcapillary tubes where individually labeled molecules are detected using confocal techniques. The coded microsphere approach is used to conduct ELISA assays on polystyrene beads doped with different ratios of red and infrared dyes to code for the assay, while light from a different fluorescent reporter on the secondary antibody is used to quantify the total biomarker bound on each bead.
It is notoriously difficult to benchmark immunoassay technologies against one another. The only reasonable way to compare platforms is to use the same antibodies and controls, with the same buffers, to optimize the appropriate concentrations of capture and detection antibodies on each platform independently, and then to measure the same samples in parallel. Many published studies that compare commercial platforms also use kits obtained from different manufacturers, so the experiment actually assesses the components of the different kits on the different platforms, not the technology platform per se.
The information in Table 1 is derived from five peer-reviewed articles [43] [44] [45] [46] [47] , technical literature from the companies and our personal experience. The volumes are calculated based upon analytes at the low end of signal detection, for example cytokine-like levels at 1 pg/ml (65 fM for IL-2). The molecular sensitivity estimates are based on average values across the publications (primarily for comparison of electrochemiluminescence and coded microsphere), and our work that shows that the same antibodies are consistently 10-to 100-fold more sensitive on SMC compared with sandwich ELISA formats. Ultimately, we made the decision to use SMC because of higher sensitivity, lower CVs and the reduced work to develop high quality assays in a singleplex format, while being very conservative with sample volumes.
Case study: microfluidic immunoassays applied to Type 2 diabetes biomarker discovery & validation Miniaturization of the immunoassay format held the promise of reducing the sample volumes required and improving the reproducibility of the measurements. As we anticipated using banked serum, we did not require a platform that could perform the sample separation or preparation, although future developments of this technology may make that possible. For our Type 2 diabetes biomarker discovery program, 260 candidate proteins and other small molecules were identified through a review of the scientific literature [48] . Of these, we were able to obtain appropriate reagents (antibodies and controls) to develop assays for 89 of the candidates (Table 2) . While all 89 assays met our initial performance specifications, a significant portion of the clinical samples (>34%) fell below the limit of quantification for 31 of these assays, and these candidates were excluded from further consideration. Consequently we included data from the remaining 58 proteins in our algorithm development and have since incorporated additional pretesting development requirements to ensure all assays run in our studies produce data across the sample population (Figure 4 & Table 3 ). The 58 candidate biomarkers could be classified into five functional categories based on their roles in human biology, which include metabolic disorder, obesity, cardiovascular disorder, inflammation and cell death [38] . Assay development typically required a four-by-four matrix of primary and secondary antibody concentrations using several buffers. Standard curves were evaluated for optimal signal-to-noise and CVs at the lower limit of quantification. Measurements were performed on dilutions of spiked samples to ensure a linear recovery range. Early experiments were done on 20 serum samples to estimate the dilution range (1:5 to 1:500,000) so that the target biomarker median concentration in a population fell in the middle of the linear dynamic range of assay performance. This was optimized on a larger sample set from each cohort tested for each assay (see Figure 2; 'Sample ranging'), to account for differences in the measured levels of different biomarkers in each cohort.
Sandwich immunoassays in the SMC format typically used a monoclonal capture antibody and a fluorescently labeled detection antibody, which was either monoclonal, mixed monoclonal or polyclonal. In our studies, samples were diluted in assay buffer to an optimal concentration for detection as determined by the sample ranging experiments. The assays were performed in 384-well format, with one biomarker measured per plate, using an average of 1.3 µl of serum in a total assay volume of 20 µl per well. Each plate included three sample replicates, six replicates of an eight-point analyte standard curve, serum control replicates (pooled human serum), antihost species control replicates (Alexa Fluor 647-labeled antibody against the capture antibody host species), no-analyte control replicates, replicates of four instrument calibrators (known amounts of Alexa Fluor 647-labeled antibody) and four control serum samples that were run across every plate for every experiment. Biomarker concentrations were calculated as the mean of the three sample replicates. Typically, assays had dynamic ranges of 10 2 to 10 3 (2 to 3 orders of magnitude), inter-plate CVs of ≤15%, and an average LLOD of 10 pg/ml [48] .
Discovery
For our initial discovery experiments, we used a subset of 3046 individuals from a populationbased study from Denmark (Inter99), which was designed as a lifestyle intervention trial for cardiovascular events [49] . Serum samples taken at the beginning of the study from 160 individuals who progressed to develop Type 2 diabetes within 5 years were analyzed along with samples from 472 individuals who were randomly selected from among those who did not develop Type 2 diabetes, to provide an approximately 3:1 ratio of non-converters to converters.
The dataset from the discovery experiments required approximately 156,000 individual analyte measurements, and took 8 weeks to generate (Figure 2 ; 'Biomarker data'). This data was analyzed using multiple statistical approaches designed to select a limited number of the most informative biomarkers. A total of 64 candidate biomarkers, six routine laboratory measures (fasting plasma glucose, fasting serum insulin, triglycerides, total cholesterol, highand low-density lipoprotein-cholesterol) and 58 serum proteins, were evaluated for inclusion in a multibiomarker algorithm. Biomarker candidates were selected for algorithm evaluation based on their selection frequency using a suite of statistical methods, including univariate logistic regression analyses, exhaustive enumeration of small multivariate logistic models, and heuristic model-building methods. Parsimonious models were emphasized by employing stepwise selection techniques while minimizing goodness-of-fit measures. The algorithm with the best performance included the levels of seven biomarkers: adiponectin, C-reactive protein, ferritin heavy chain 1, glucose, glycated hemoglobin, IL-2 receptor subunit a and insulin [48] . Figure 5a shows the graph of the logistic regression algorithm based on the seven biomarkers. The output of the algorithm is a score from 1 to 10, which we call the diabetes risk score (DRS), with 1 having the lowest risk and 10 the highest. Figure 5b demonstrates that the DRS has statistically better performance than many common risk factors associated with Type 2 diabetes.
Research validation Using the SMC, we validated the performance of the DRS on a Finnish cohort -the Botnia Study [50] . This family-based study tracked 2770 individuals for up to 15 years. Using the algorithm developed with the Inter99 cohort samples, 136 converters and 2214 nonconverters from the Botnia cohort were tested to evaluate the performance of the DRS [51, 52] . The results 
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Clinical validation
We transitioned from the research phase to the development phase, transferring all seven assays to commercial immunoassay platforms in our CLIA certified laboratory. We then revalidated the algorithm using the Inter99 cohort and a second cohort, Botnia [38] , using these same commercial platforms. We have since tested the Insulin Resistance Atherosclerosis Study (IRAS) cohort, which is representative of North American ethnic/racial diversity.
The PreDx Diabetes Risk Score is available at the Tethys Clinical Laboratory in Emeryville, California. At the time of writing, over 400 physicians were using the test to assess the risk of diabetes in their patients. More than 40,000 patients have been tested.
Case study summary & conclusion
In the planning phases of our biomarker program for Type 2 diabetes, we faced the major decision to pursue a hypothesis-free discovery approach using MS or a candidate-driven discovery approach using immunoassays. Both approaches entailed certain proteome coverage limitations. However, the risks associated with failing to identify good candidates, expending large amounts of resources following up 'falsepositive' candidates and the availability of samples with sufficient volume, were quite different in the two approaches. Ultimately, miniaturized immunoassay-based technology was the only approach available to us that allowed us to exploit the very small quantities of serum samples that were available in banked samples from appropriate cohorts. The SMC platform greatly enabled our discovery and validation research programs by facilitating the application of low volume, reproducible and analytically sensitive (i.e., low limit of quantification) assays that could be performed in high-throughput protocols, which allowed us to evaluate a relatively large number of candidates. The evaluation of a large number of candidates is critical to identifying the best biomarkers for each of the various biological pathways that are affected in complex diseases. By using the same format (sandwich immunoassay) in the research phases that is used on commercial platforms, we reduced the risk and time associated with the development phase of the project. We were able to complete the research phase in 18 months and the development phase in 6 months. The success of this diagnostic development program, which generated a multibiomarker diagnostic test that provides a significant improvement over currently available tools for stratifying diabetes risk, along with biomarker programs for other diseases that have been reported recently [25, 53] , illustrates that viable approaches for systematically identifying and validating multibiomarker tests for complex diseases are available. We have also applied the approach outlined here successfully to primary myocardial infarction risk and osteoporotic fracture risk [201, 201] .
Future perspective
Cu rrent approache s for de velopi ng multibiomarker diagnostic tests, such as the approach described in this article, have enabled the development of powerful new clinical tools. These technologies are still in their infancy and we can expect future generations of tests to benefit as the ability to interrogate the biology of disease scales with improvements in technology. In the future, four critical areas of improvement will enable the rapid expansion of proteomic biomarker discovery and validation: coverage, molecular sensitivity, throughput and sample volume requirements. There are different constraints on each of these variables, impacted in different ways when considering specific technological solutions.
Coverage
An important driver of the future evolution of biomarker discovery is the desire of researchers to analyze a larger fraction of the proteome and, therefore, of the biological space. There are essentially two main approaches: reagentfree proteomics and reagent-dependent proteomics [54] . The major advancements in reagent-free proteomics are occurring in the field of MS [34] but the technology has numerous challenges. Continued advancement in multiple reaction monitoring and other MS techniques along with advances in separation technologies, particularly microfluidic separation approaches [55, 56] , could improve the ability of investigators to analyze complex biological samples with increased coverage over the current state of the art. Ultimately, complete or near-complete coverage of a complex proteome using MS will enable hypothesis-free experiments. However, this is likely to require another 5-10 years of innovation. The alternative approach, reagent-dependent proteomics, has different constraints. Using affinity-based methods (e.g., immunoassays), only a few hundred proteins can currently be measured out of Microfluidic strategies for biomarker discovery & validation for multivariate diagnostics | Review www.future-science.com the 3000 or so proteins known to be present in blood (not including the complexity added by protein isoforms, exon rearrangements and post-translational modifications). An ambitious project to create a complete set of antibody reagents for the human proteome is in progress, and is scheduled to have a complete set of reagents by 2015 [57] . Multiple affinity reagent platforms are available for both in vivo and in vitro affinity-based strategies, including engineered antibody libraries [58] , non-antibody protein scaffolds [59] , aptamers [54] and small molecules [60] . These reagents will create new resources and capabilities, and, ultimately, yield a complete set of affinity-based reagents that can be used to measure the human proteome and enable unbiased biomarker discovery. One example of recent progress to increase coverage of the serum proteome is an aptamer-based biomarker discovery technology that has recently been reported to cover >800 proteins [61] .
Molecular sensitivity
Of course, single-molecule detection and quantification is the ultimate goal. Many methods already exist, but a major question is: are these methods practical given the naturally occurring concentration of molecular biomarkers within a sample? Figure 6 shows how many molecules of analyte are present at different volumes and concentrations. At detection limits in the 10-100 fM range, it is currently possible to detect 6000-60,000 molecules in 1 µl. If 60 molecules must be measured to obtain reasonable CVs based upon Poisson distribution within a sample, then there is an opportunity for 2 to 3 logs of sensitivity improvement. There are a variety of biophysical techniques that are pushing the limits of molecular detection into the aM range and beyond, including fluorescence [62] , nanostructure-based effects [63] [64] [65] [66] [67] [68] [69] [70] , surface plasmon resonance [71] [72] [73] and Raman scattering approaches [74] . Many of these technologies still reside in the low-throughput research laboratory and translation to broadbased, routine and quantitative use remains a hurdle for these to have a significant impact on future biomarker discovery capabilities. A recent promising approach is an ultrasensitive single molecule ELISA assay platform that has reported sensitivities in the aM and below range [75] . There could be single assay opportunities for technologies such as these that can have an impact on commercial clinical diagnostics but several challenges related to increasing protein coverage, sample volume and handling and assay throughput remain for these detection technologies to be effective biomarker discovery platforms. Nevertheless, much progress has been made and given the activity in this area, a routine molecular sensitivity of 10 fM (600 molecules/100 nl) is a reasonable specification for future technologies.
Sample volume
As coverage improves the demand for more efficient sample utilization increases. For experimental approaches that perform singleplex analyses, an experiment that aims to measure 1000 analytes in triplicate would require 3 ml of each sample if the sample volume of each assay is 1 µl. This is significantly greater than the sample volumes that are typically available from valuable sample collections. A more practical volume specification is a total of 300 µl of each sample per experiment, which would constrain the total assay volume to 100 nl to measure 1000 analytes (as singleplex assays performed in triplicate).
There are two solutions to reducing sample volume requirements, multiplexing and microfluidics. Multiplexing using sandwich immunoassay formats has been refined for over a decade, and there are reliable formats for assaying biomolecules that occur at similar concentrations [47] . Although there continue to be significant hurdles for analytical validation and quality control for multiplex assays for use in the in vitro diagnostic market [76, 77] , these concerns may be less important for the use of multiplex assays in discovery and research validation. From a sample volume perspective, for multiplexed assays to go from 5 µl per assay to 100 nl per assay, it would require an increase in multiplexing from ten-fold to 500-fold using the same total assay volumes that are currently used. Improvements in either the specificity of binding reagents (which would allow a higher multiplexing density), or detection sensitivity (which would reduce sample volume requirements), have the potential to increase the level of multiplexing within a unit sample volume and thus reduce the amount of sample used per assay. One recent report described multiplexed homogenous proximity ligation assays consisting of four 24-plex panels covering 74 putative protein with sub-pM sensitivities and requiring only 1 µl of human plasma [78] . Pushing plex limits to new heights is an innovative, highly multiplexed capture and detection format based on aptamers (mentioned previously), which has been deployed for biomarker discovery and research validation in lung cancer [79] and chronic kidney disease [61] . By combining highly-selective nucleic acid protein binders and stringent binding and washing techniques, the researchers achieved a highly-multiplexed format (>800 assays) with median lower limits of detection of 1 pM. In addition, specific hybridization tags engineered on each aptamer allow detection on standardized microarray formats, which simplifies biomarker measurements. This approach looks promising for future biomarker discovery efforts.
Microfluidics provides a number of unique advantages compared with the conventional benchtop systems used for processing and separating biological samples for MS and other biomarker analyses, including reduced sample and reagent consumption, improved speed, process step integration for fully automated systems and the ability to parallelize processes and increase sample processing throughput. The various strategies in development are highly varied, with liquid movement driven by capillary, pressure, centrifugal, electrokinetic and acoustic forces (see [80] for comprehensive review). Currently, two platforms appear to best meet the requirements of high-throughput ana lysis, low sample volume and the medium sample processing complexity: segmented flow and centrifugal flow microfluidics [81] . Figure 2 , for discovery programs that use affinity-based analyses, the speed of the analytical steps is not the rate-limiting step in the context of a large biomarker discovery project if a miniaturized, high-throughput analytical platform is used. However, as the coverage increases (i.e., a larger number of analytes will be measured), the throughput parameters become a significant issue. For instance, to analyze 1000 biomarkers in triplicate in 5000 samples requires 15 million analytical measurements, which would require the analysis of over 52,000 384-well plates using the SMC platform -a staggering amount of work. Multiplex technologies have an advantage here, reducing the number of sampling points linearly with the multiplex density. In the best case, with 1000 multiplexed aptamers as cited earlier [61] , the rate limiting step becomes the microarray scanning, where the experiment described above would require 15,000 microarrays. This is still a very substantial amount of work, even with sophisticated infrastructure. A potential relief to this scaling problem should come from microf luidics, where parallel processing of nanovolumes of sample is fast and reproducible. Although a fully integrated system for immunoassay measurements that seamlessly combines sample processing and detection is alluring, the integration of all of these components is not necessarily required for the applications of biomarker discovery and biomarker validation. Microfluidics systems that perform even one of these major steps -sample preparation, analytical steps, or detection -can greatly enable throughput bottlenecks. If the discovery phase of a program such as that described earlier should not take more than 2 months, then the technology would need to be capable of processing on the order of 400,000 assays per day. This throughput is within reach given the significant advances in microfluidics experienced recently but to be fully realized requires development of the onetime research demonstrations into robust production-ready platforms for sustained biomarker discovery and validation applications.
Throughput
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Integration of performance
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Molecules/nl Molecules/µl Molecules/ml Microfluidic strategies for biomarker discovery & validation for multivariate diagnostics | Review www.future-science.com solution for unbiased proteomic discovery using affinity reagents will require innovations in several technology areas. Table 4 compares the capabilities of current immunoassaybased proteomic technologies to the desired specification detailed here.
Analyte concentration
For each performance area, there is an opportunity for more than a log of improvement, translating to a 10,000-fold overall improvement for our ideal technology solution. This is a challenging, but not improbable goal. DNA sequencing capability has gone from 10 3 -10 8 base pairs per day over less than two decades and expression profiling has gone through similar technological leaps. In addition, combining of advances from two or more areas will create new paradigms in biomarker measurement. For example, as single molecule measurements advance and are combined with segmented flow microfluidics, stochastic methods of quantitative measurements will be possible. This digital counting of segmented sample volumes, that either contain the molecule of interest or not, will allow for back calculation of a given analyte concentration in the original sample. A distinct advantage that is created from this combination is that the sensitivity of the analytical measurement only needs to be as good as the concentration of the molecule in the segmented volume (i.e., higher than in the bulk sample).
Final thoughts
The scientific and medical communities have only begun to tap the potential value of multibiomarker tests. For most complex diseases, it is likely that the ana lysis of multiple biomarkers will be required to provide the sensitivity and specificity needed for clinical tests that will be used for risk assessment, prognosis, intervention selection and monitoring the effects of interventions. We describe here some of the challenges that face every protein biomarker discovery effort. For clinical applications, the standards of performance and validation are quite high, yet as we demonstrate in the case study, current commercially available analytical platforms can take a program all the way from the discovery research phase to application in the clinical diagnostics market in as little as 2 years.
We have not addressed the advances that are occurring in commercial clinical diagnostic applications, as they have a very different set of user requirements than the platforms (or components) used for discovery and validation applications. For commercial diagnostics, sample conservation is not necessarily as important, though turnaround time often is. In addition, in clinical diagnostics there is a much lower tolerance for operational complexity and, therefore, significant investments to improve the ease-of-use of a device must often be made, allowing deployment in settings such as doctors' offices, hospital emergency rooms and low-resource areas in the developing world. Therefore, many of the microfluidic biomarker detection prototype devices designed for commercial clinical diagnostic use that have been reported thus far aim to fully integrate sample processing, ana lysis and detection (for instance, see Mark et al. [80] for descriptions of several currently marketed products, and [82] , [83] and [84] for platforms under development). It is important not to lose track of the commercial platform capabilities. It is not useful to use an esoteric, ultrasensitive platform if the assays cannot be translated to the targeted commercial platforms. The proteins we found to be useful in the DRS algorithm were at a sufficiently high concentration that standard clinical chemistry and immunoassay platforms could be employed. It is far easier, faster and cheaper to develop a standard clinical assay with new proteins and old technology than with new technology.
We believe that microfluidic approaches will continue to play a significant role in increasing the coverage of the proteome that can be observed in biomarker discovery, enabling biomarker validation, and changing the way biomarkers are measured in commercial clinical diagnostic platforms. Sample volume limitations, molecular sensitivity requirements and the number of analytes that need to be interrogated for discovery purposes necessitated our use of improved technologies versus standard methods for research. While the example of the development of a multimarker diabetes risk test described in this article is one of the most comprehensive screens that has been reported to date, the process operated at the performance limits of current technology and tapped only a fraction of the biological space. A tenfold improvement in coverage and molecular sensitivity, while correspondingly reducing the sample volume per assay by tenfold, would make it possible to cover a significant fraction of the proteome biomarker space, which would constitute a switch from the candidate biomarker approach we describe here to an empirical approach that we desire but have not yet achieved.
